# NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma

> **NCT07740941** · PHASE2 · RECRUITING · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 55 (estimated)

## Conditions studied

- Melanoma (Skin Cancer)
- Melanoma Stage Stage IIIB
- Melanoma Stage M1
- Melanoma Stage IV

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Ipilimumab plus nivolumab

## Key facts

- **NCT ID:** NCT07740941
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-06
- **Primary completion:** 2029-03
- **Final completion:** 2029-03
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2026-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07740941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07740941, "NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07740941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*